{"id":"alogliptin-and-voglibose","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL476960","moleculeType":"Small molecule","molecularWeight":"267.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alogliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones, thereby increasing the levels of incretin hormones in the body. This leads to increased insulin release in response to meals and decreased glucagon levels in the circulation during the postprandial period. Voglibose, on the other hand, works by inhibiting the enzyme alpha-glucosidase, which breaks down carbohydrates into simple sugars, thereby slowing the absorption of glucose from the gut.","oneSentence":"Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while voglibose is an alpha-glucosidase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:14.432Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01263483","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Type 2 Diabetes Mellitus","enrollment":230},{"nctId":"NCT01263470","phase":"PHASE2","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01263509","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Type 2 Diabetes Mellitus","enrollment":179}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SYR-322","BASEN®","Voglibose"],"phase":"phase_2","status":"active","brandName":"Alogliptin and voglibose","genericName":"Alogliptin and voglibose","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while voglibose is an alpha-glucosidase inhibitor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}